bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure Legends, Figures 1 - 4 from Aurora Kinase Inhibition Induces PUMA via NF-κB to Kill Colon Cancer Cells
Authors: Sun Jing , Knickelbein Kyle , He Kan , Chen Dongshi , Dudgeon Crissy , Shu Yongqian , Yu Jian , Zhang Lin
Published: April 2023

PDF file - 364KB, Figure S1: p53-independent PUMA induction by the aurora kinase inhibitor VX-680 in colon cancer cells; Figure S2: PUMA mediates the apoptotic and anticancer activities of ZM-447439 and VX-680; Figure S3: Analysis of transcription factors and kinases involved in PUMA induction by aurora kinase inhibitors; Figure S4: Analysis of kinase pathways involved in PUMA induction by aurora kinase inhibitors.
Supplementary Table 2 from Contribution of ATM and ATR to the Resistance of Glioblastoma and Malignant Melanoma Cells to the Methylating Anticancer Drug Temozolomide
Authors: Eich Marcus , Roos Wynand Paul , Nikolova Teodora , Kaina Bernd
Published: April 2023

PDF file - 78 KB, Apoptosis and necrosis rates of cell death data for fibroblasts and lymphoblastoid cells
Supplementary Figure 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo
Authors: Beider Katia , Darash-Yahana Merav , Blaier Orly , Koren-Michowitz Maya , Abraham Michal , Wald Hanna , Wald Ori , Galun Eithan , Eizenberg Orly , Peled Amnon , Nagler Arnon
Published: April 2023

PDF - 90K, Demonstrates CXCR4 expression and function in K562 and K562LG-CXCR4 cells.
Supplemental Methods from Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody
Authors: Leonard John E. , Fisher Terrence L. , Winter Laurie A. , Cornelius Chad A. , Reilly Christine , Smith Ernest S. , Zauderer Maurice
Published: April 2023

Supplemental Methods: Nonclinical Safety Evaluation of VX15/2503; a Humanized IgG4 Anti-SEMA4D Antibody
Supplementary Figures 1 - 3 from Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
Authors: Guertin Amy D. , Li Jing , Liu Yaping , Hurd Melissa S. , Schuller Alwin G. , Long Brian , Hirsch Heather A. , Feldman Igor , Benita Yair , Toniatti Carlo , Zawel Leigh , Fawell Stephen E. , Gilliland D. Gary , Shumway Stuart D.
Published: April 2023

PDF file - 724K, S1. MK-1775 treatment inhibits proliferation in diverse tumor cell lines. S2. DNA damage induction by MK-1775 treatment requires mitogen stimulation. S3. The MK-1775 response of three sensitive cell lines.
Supplementary Figure Legend from Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
Authors: Guertin Amy D. , Li Jing , Liu Yaping , Hurd Melissa S. , Schuller Alwin G. , Long Brian , Hirsch Heather A. , Feldman Igor , Benita Yair , Toniatti Carlo , Zawel Leigh , Fawell Stephen E. , Gilliland D. Gary , Shumway Stuart D.
Published: April 2023

PDF file - 91K
Supplementary Table 3 from GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling
Authors: Duffy David J. , Krstic Aleksandar , Schwarzl Thomas , Higgins Desmond G. , Kolch Walter
Published: April 2023

PDF - 61K, Table S3. Alignment scores of GSK3 inhibitor mRNA-seq reads in IMR32 cells with TopHat.
Supplementary Table 2 from GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling
Authors: Duffy David J. , Krstic Aleksandar , Schwarzl Thomas , Higgins Desmond G. , Kolch Walter
Published: April 2023

PDF - 98K, Table S2. Flow Cytometry full details in accordance with the MIFlowCyt Standard.
Supplementary Table S1 from Triptolide Induces the Expression of miR-142-3p: A Negative Regulator of Heat Shock Protein 70 and Pancreatic Cancer Cell Proliferation
Authors: MacKenzie Tiffany N. , Mujumdar Nameeta , Banerjee Sulagna , Sangwan Veena , Sarver Aaron , Vickers Selwyn , Subramanian Subbaya , Saluja Ashok K.
Published: April 2023

Supplementary Table S1 - PDF file 53K, Statistics for all miRNAs from microarray
Supplementary Figure 1 from Triptolide Induces the Expression of miR-142-3p: A Negative Regulator of Heat Shock Protein 70 and Pancreatic Cancer Cell Proliferation
Authors: MacKenzie Tiffany N. , Mujumdar Nameeta , Banerjee Sulagna , Sangwan Veena , Sarver Aaron , Vickers Selwyn , Subramanian Subbaya , Saluja Ashok K.
Published: April 2023

Supplementary Figure 1 - PDF file 33K, Principle components analysis
Supplementary Figure Legends from Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth
Authors: Campbell Veronica T. , Nadesan Puviindran , Ali S. Amanda , Wang Chang Ye Yale , Whetstone Heather , Poon Raymond , Wei Qingxia , Keilty John , Proctor Jennifer , Wang Lauren W. , Apte Suneel S. , McGovern Karen , Alman Benjamin A. , Wunder Jay S.
Published: April 2023

PDF - 62K, Legends for Supplementary Figures 1 and 2.
Supplementary Figure 1 from Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth
Authors: Campbell Veronica T. , Nadesan Puviindran , Ali S. Amanda , Wang Chang Ye Yale , Whetstone Heather , Poon Raymond , Wei Qingxia , Keilty John , Proctor Jennifer , Wang Lauren W. , Apte Suneel S. , McGovern Karen , Alman Benjamin A. , Wunder Jay S.
Published: April 2023

PDF - 516K, Hh signaling in normal mouse chondrocytes is inhibited by IPI-926 treatment and leads to growth plate closure. A. Active control growth plate with a normal appearance. B. Corresponding growth plate from an IPI-926 treated mouse shows premature closure (indicated by black arrow).
Supplementary Materials and Methods and Supplementary Figure Legends from Regulation of SRC Kinases by microRNA-3607 Located in a Frequently Deleted Locus in Prostate Cancer
Authors: Saini Sharanjot , Majid Shahana , Shahryari Varahram , Tabatabai Z. Laura , Arora Sumit , Yamamura Soichiro , Tanaka Yuichiro , Dahiya Rajvir , Deng Guoren
Published: April 2023

PDF - 91K, Supplemental materials and methods and figure legends to Fig. S1, S2, S3 and Table S1.
Supplementary Figure 5 from EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis
Authors: Son Ji Yeon , Park So-Yeon , Kim Sol-Ji , Lee Seon Joo , Park Sang-A. , Kim Min-Jin , Kim Seung Won , Kim Dae-Kee , Nam Jeong-Seok , Sheen Yhun Yhong
Published: April 2023

PDF - 356K, (A~C) Breast cancer model #1, described in the Material and Methods. (A) Effect of EW-7197 on lung metastasis of breast cancer in MMTV-c/Neu mice. Representative images of H&E stained lungs (total magnification: x 12.5 or 100, scale bar: 800 μm or 100 μm). Total tumor volume (B) and body weight (C) in MMTV/c-Neu mice. Data represent the mean (plus or minus) SE (Veh: n=7, EW: n=10). (D and E) Body weight in breast cancer model #2 (D) and in breast cancer model #3 (E) (described in the Material and Methods). Data represent the mean (plus or minus) SE (n=10/group in Model #2 or n=6~8/group in Model #3). Veh, LY and EW indicate artificial gastric fluid, LY-2157299 and EW-7197, respectively. (F) In breast cancer model #3 (described in the Material and Methods), on day 28, two mice of each group were selected and treated with the indicated concentration of EW-7197. One mouse from each group was injected with TGF-beta1 (50 ng/mouse) through i.v. after 30 min and another was not injected. 90 min after TGF-beta1 injection, mice were sacrificed and lysates from primary mammary tumors were analyzed by western blotting as described in the Material and Methods.
Supplementary Methods, Figures 1 - 9 from Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance
Authors: Aoyama Aki , Katayama Ryohei , Oh-hara Tomoko , Sato Shigeo , Okuno Yasushi , Fujita Naoya
Published: April 2023

Supplementary method and Figures. Figure S1 contains expression levels of c-MET in the cells used in this paper. Figure S2 contains the photographs taken after treatment with microtubule inhibitor. Figure S3 contains Immunohistochemistry of tubulin after tivantinib treatment. Figure S4 contains the photographs indicated the effect of tivantinib on tubulin. Figure S5 contains immunoblot data of various cells treated with various microtubule inhibitors. Figure S6 contains mouse body weight change and immunoblot data of xenografts. Figure S7 contains the data of tubulin competition assay using various inhibitors. Figure S8 contains the result of docking simulation using GOLD docking program. Figure S9 contains the data of apoptotic cell after drug treatment.
Supplementary Figures 1 - 10, Tables 1 - 2 from Aerosol Administration of Phospho-Sulindac Inhibits Lung Tumorigenesis
Authors: Cheng Ka Wing , Wong Chi C. , Alston Ninche , Mackenzie Gerardo G. , Huang Liqun , Ouyang Nengtai , Xie Gang , Wiedmann Timothy , Rigas Basil
Published: April 2023

PDF file - 883K
Supplementary Table 1 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
Authors: Kai Kazuharu , Kondo Kimie , Wang Xiaoping , Xie Xuemei , Pitner Mary K. , Reyes Monica E. , Torres-Adorno Angie M. , Masuda Hiroko , Hortobagyi Gabriel N. , Bartholomeusz Chandra , Saya Hideyuki , Tripathy Debu , Sen Subrata , Ueno Naoto T.
Published: April 2023

Profiles of cell lines used in the present study.
Supplementary Tables 1 and 2 from ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
Authors: Zhang Li , Castanaro Carla , Luan Bo , Yang Katie , Fan Liangfen , Fairhurst Jeanette L. , Rafique Ashique , Potocky Terra B. , Shan Jing , Delfino Frank J. , Shi Ergang , Huang Tammy , Martin Joel H. , Chen Gang , MacDonald Douglas , Rudge John S. , Thurston Gavin , Daly Christopher
Published: April 2023

PDF - 56K, Measurement of REGN1400 and REGN955 binding affinities.
Supplementary Figure 4 from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
Authors: Swers Jeffery S. , Grinberg Luba , Wang Lin , Feng Hui , Lekstrom Kristen , Carrasco Rosa , Xiao Zhan , Inigo Ivan , Leow Ching Ching , Wu Herren , Tice David A. , Baca Manuel
Published: April 2023

PDF file - 98K, Supplementary Figure S4: Caspase activation by G6T8.
Supplementary Figure 1 from Overexpression of DDX43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma Cells
Authors: Ambrosini Grazia , Khanin Raya , Carvajal Richard D. , Schwartz Gary K.
Published: April 2023

PDF file - 39K, The selumetinib-resistant UM cells are also resistant to other MEK inhibitors.
Supplementary Materials and Methods from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Authors: Gross Matt I. , Demo Susan D. , Dennison Jennifer B. , Chen Lijing , Chernov-Rogan Tania , Goyal Bindu , Janes Julie R. , Laidig Guy J. , Lewis Evan R. , Li Jim , MacKinnon Andrew L. , Parlati Francesco , Rodriguez Mirna L.M. , Shwonek Peter J. , Sjogren Eric B. , Stanton Timothy F. , Wang Taotao , Yang Jinfu , Zhao Frances , Bennett Mark K.
Published: April 2023

PDF - 246K, Supplementary Materials and Methods.
Supplementary Figure 4 from XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer
Authors: Cheng Yan , Holloway Michael P. , Nguyen Kevin , McCauley Dilara , Landesman Yosef , Kauffman Michael G. , Shacham Sharon , Altura Rachel A.
Published: April 2023

PDF file - 51K, Knockdown of XIAP has no effect on survivin degradation.
Supplementary Table S1 from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
Authors: Burbridge Mike F. , Bossard Céline J. , Saunier Carine , Fejes Imre , Bruno Alain , Léonce Stéphane , Ferry Gilles , Da Violante Georges , Bouzom François , Cattan Valérie , Jacquet-Bescond Anne , Comoglio Paolo M. , Lockhart Brian P. , Boutin Jean A. , Cordi Alex , Ortuno Jean-Claude , Pierré Alain , Hickman John A. , Cruzalegui Francisco H. , Depil Stéphane
Published: April 2023

Pharmacokinetic parameters of S49076 administered orally to female balb/c nu/nu mice
Supplementary Figure 4 from Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
Authors: Acquaviva Jaime , Smith Donald L. , Jimenez John-Paul , Zhang Chaohua , Sequeira Manuel , He Suqin , Sang Jim , Bates Richard C. , Proia David A.
Published: April 2023

PDF file - 378K, Inhibition of BRAF V600E enhances the activity of the MEK inhibitor AZD6244 in vemurafenib-resistant melanoma cells.
Supplementary Figure S4 from Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model
Authors: Sia Kian Chuan , Huynh Hung , Chung Alexander Yaw Fui , Ooi London Lucien Peng Jin , Lim Kiat Hon , Hui Kam Man , Lam Paula Yeng Po
Published: April 2023

Supplementary Figure S4 - PDF file 160K, Immunohistochemistry analysis on primary HCC and RCC tumor sections. A, Primary HCC 26-1004 and B, primary RCC 09-1210C. Tumor sections were stained with antibodies against human fibroblast, human nuclei and proliferation marker Ki-67. Similar concentrations of mouse IgG1 antibodies were used as negative control. Scale bar = 50 microm
Supplementary Figure S1 from Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model
Authors: Sia Kian Chuan , Huynh Hung , Chung Alexander Yaw Fui , Ooi London Lucien Peng Jin , Lim Kiat Hon , Hui Kam Man , Lam Paula Yeng Po
Published: April 2023

Supplementary Figure S1 - PDF file 87K, Gene expression of AH-6CC-L2C in proliferating and G1-arrested PLC/PRF/5 cells. Cell cycle-regulated luciferase reporter activity in proliferating and G1-arrested PLC/PRF/5 cells after 48 h in A, post transfection with pAH-6CC-L2C or B, post infection with AH-6CC-L2C at MOI of 1. Total RLU was normalized with total protein contents and % of eGFP-positive cells representing the transfection efficiency. Data were presented as mean plus-minus SEM, n = 3. C, Corresponding cell cycle profiles of proliferating and G1-arrested PLC/PRF/5 cells as analyzed by FACS analysis
Supplementary Figure Legends from Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model
Authors: Sia Kian Chuan , Huynh Hung , Chung Alexander Yaw Fui , Ooi London Lucien Peng Jin , Lim Kiat Hon , Hui Kam Man , Lam Paula Yeng Po
Published: April 2023

Supplementary Figure Legends - PDF file 83K, Supplementary Figure legends for Figure S1, S2, S3, S4, S5, S6, S7 and S8
Supplementary Methods from Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response
Authors: Cesca Marta , Morosi Lavinia , Berndt Alexander , Nerini Ilaria Fuso , Frapolli Roberta , Richter Petra , Decio Alessandra , Dirsch Olaf , Micotti Edoardo , Giordano Silvia , D'Incalci Maurizio , Davoli Enrico , Zucchetti Massimo , Giavazzi Raffaella
Published: April 2023

Materialds and Methods details concerning MALDI MSI, Immunihistochemistry and DCE-MRI
Supplementary Table 2 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
Authors: Kung Pei-Pei , Martinez Ricardo , Zhu Zhou , Zager Michael , Blasina Alessandra , Rymer Isha , Hallin Jill , Xu Meirong , Carroll Christopher , Chionis John , Wells Peter , Kozminski Kirk , Fan Jeffery , Guicherit Oivin , Huang Buwen , Cui Mei , Liu Chaoting , Huang Zhongdong , Sistla Anand , Yang Jennifer , Murray Brion W.
Published: April 2023

PDF - 98K, Effect of PF-2771 on breast cell line proliferation and CIN index analysis.
Supplementary Figure 1 from Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response
Authors: Cesca Marta , Morosi Lavinia , Berndt Alexander , Nerini Ilaria Fuso , Frapolli Roberta , Richter Petra , Decio Alessandra , Dirsch Olaf , Micotti Edoardo , Giordano Silvia , D'Incalci Maurizio , Davoli Enrico , Zucchetti Massimo , Giavazzi Raffaella
Published: April 2023

MALDI MSI images from A2780-1A9 subcutis tumors described in Fig. 2, of the Results and Discussion, were quantified for ion signal distribution.
Supplementary Figure 2 from Blocking SDF-1α/CXCR4 Downregulates PDGF-B and Inhibits Bone Marrow–Derived Pericyte Differentiation and Tumor Vascular Expansion in Ewing Tumors
Authors: Hamdan Randala , Zhou Zhichao , Kleinerman Eugenie S.
Published: April 2023

PDF - 49K, Quantification data showing that fewer GFP+ cells are present in the tumors from AMD 3100 compared to PBS at the time of tumor resection.
Supplementary Figure 1 from Blocking SDF-1α/CXCR4 Downregulates PDGF-B and Inhibits Bone Marrow–Derived Pericyte Differentiation and Tumor Vascular Expansion in Ewing Tumors
Authors: Hamdan Randala , Zhou Zhichao , Kleinerman Eugenie S.
Published: April 2023

PDF - 54K, Western blot analysis showing that while the study cells TC71 and A4573 express CXCR4, CXCR7 protein expression is low.
Supplementary Figure 1 from Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Kuzu Omer F. , Sharma Arati , Robertson Gavin P.
Published: April 2023

PDF - 95K, Leelamine inhibits three key signaling pathways regulating melanoma development.
Supplementary Figure from Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome–Positive Lymphoid Leukemia
Authors: Nemoto Atsushi , Saida Satoshi , Kato Itaru , Kikuchi Jiro , Furukawa Yusuke , Maeda Yasuhiro , Akahane Koshi , Honna-Oshiro Hiroko , Goi Kumiko , Kagami Keiko , Kimura Shinya , Sato Yuko , Okabe Seiichi , Niwa Akira , Watanabe Kenichiro , Nakahata Tatsutoshi , Heike Toshio , Sugita Kanji , Inukai Takeshi
Published: April 2023

Supplementary Fig. S1-S5. Fig. S1. Anti-leukemic activity of PD0332991 against Ph+ lymphoid leukemia cell lines. Fig. S2. Effect of cytokines and PD0332991 on cell growth of Ph+ lymphoid leukemia cell lines. Fig. S3. Anti-leukemic activity of PD0332991 against a Ph+ALL cell lines with a T315I mutation of BCR-ABL in vitro. Fig. S4. Anti-leukemic activity of PD0332991 against a Ph+ ALL cell line with a T315I mutation of BCR-ABL in a xenograft model using NOG mice. Fig. S5. Expression of cell cycle regulators in Ph+ lymphoid leukemia cells.
Supplementary Figure 1 from Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer
Authors: Brand Toni M. , Iida Mari , Dunn Emily F. , Luthar Neha , Kostopoulos Kellie T. , Corrigan Kelsey L. , Wleklinski Matthew J. , Yang David , Wisinski Kari B. , Salgia Ravi , Wheeler Deric L.
Published: April 2023

PDF - 3969K, Supplemental Figure 1. Therapeutic inhibition of SFKs can block nEGFR translocation in colorectal tumor models.
Supplementary Figure 2 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Authors: Kunoh Tatsuki , Noda Takanori , Koseki Koichi , Sekigawa Masayuki , Takagi Motoki , Shin-ya Kazuo , Goshima Naoki , Iemura Shun-ichiro , Natsume Tohru , Wada Shu-ichi , Mukai Yukio , Ohta Shinji , Sasaki Ryuzo , Mizukami Tamio
Published: April 2023

Supplementary Figure 2 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Supplementary Figure Legend from Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model
Authors: Narita Yusuke , Okamoto Kiyoshi , Kawada Megumi Ikemori , Takase Kazuma , Minoshima Yukinori , Kodama Kotaro , Iwata Masao , Miyamoto Norimasa , Sawada Kohei
Published: April 2023

PDF - 50K, Legends for Supplementary Figures 1 through 4.
Supplementary Figure 1 from MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189
Authors: Wang Wei , Wang Ying-Qing , Meng Tao , Yi Jun-Mei , Huan Xia-Juan , Ma Lan-Ping , Tong Lin-Jiang , Chen Yi , Ding Jian , Shen Jing-Kang , Miao Ze-Hong
Published: April 2023

PDF - 18K, The chemical structure of MT189 and its synthesis approach.
Supplementary Table 2 from Marine Sponge Cribrochalina vasculum Compounds Activate Intrinsic Apoptotic Signaling and Inhibit Growth Factor Signaling Cascades in Non–Small Cell Lung Carcinoma
Authors: Zovko Ana , Viktorsson Kristina , Hååg Petra , Kovalerchick Dimitry , Färnegårdh Katarina , Alimonti Andrea , Ilan Micha , Carmeli Shmuel , Lewensohn Rolf
Published: April 2023

Supplementary Table 2: NMR data of (3S)-14-methyldocos-4E-en-1-yn-3-ol (2).
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
Authors: Dermawan Josephine Kam Tai , Gurova Katerina , Pink John , Dowlati Afshin , De Sarmishtha , Narla Goutham , Sharma Neelesh , Stark George R.
Published: April 2023

Supplementary figure S1
Supplemental figure legends from Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression
Authors: Teicher Beverly A. , Polley Eric , Kunkel Mark , Evans David , Silvers Thomas , Delosh Rene , Laudeman Julie , Ogle Chad , Reinhart Russell , Selby Michael , Connelly John , Harris Erik , Monks Anne , Morris Joel
Published: April 2023

Supplemental figure legends text.
Supplemental Table 1 of Sarcoma cell lines from Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression
Authors: Teicher Beverly A. , Polley Eric , Kunkel Mark , Evans David , Silvers Thomas , Delosh Rene , Laudeman Julie , Ogle Chad , Reinhart Russell , Selby Michael , Connelly John , Harris Erik , Monks Anne , Morris Joel
Published: April 2023

Sarcoma cell lines that were in the screen
Supplemental figure 2 from Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression
Authors: Shang Zhiqun , Li Yanjun , Zhang Minghao , Tian Jing , Han Ruifa , Shyr Chih-Rong , Messing Edward , Yeh Shuyuan , Niu Yuanjie , Chang Chawnshang
Published: April 2023

Supplemental figure 2 HF or ASC-J9® induced THP-1 cell differentiating to M1 macrophage
Supplementary TableS3 from Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Authors: Nakanishi Yoshito , Akiyama Nukinori , Tsukaguchi Toshiyuki , Fujii Toshihiko , Satoh Yasuko , Ishii Nobuya , Aoki Masahiro
Published: April 2023

Gene signature of FGFR3-BAIAP2L1
Supplementary Figure S6 from Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Authors: Nakanishi Yoshito , Akiyama Nukinori , Tsukaguchi Toshiyuki , Fujii Toshihiko , Satoh Yasuko , Ishii Nobuya , Aoki Masahiro
Published: April 2023

Phospho-FGFR induction by FGF1
Supplementary figures S1-S5 from The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity
Authors: Chang Ki-Eun , Wei Bih-Rong , Madigan James P. , Hall Matthew D. , Simpson R. Mark , Zhuang Zhengping , Gottesman Michael M.
Published: April 2023

Supplementary figures S1-S5. Supplementary Figure S1. Western blot showing differential expression of PP2A-C (catalytic subunit) and PP2A-A (scaffold subunit) in different ovarian cancer cell lines; Supplementary Figure S2. LB100 is not a substrate for ATP-binding cassette (ABC) efflux transporters; Supplementary Figure S3. LB100 has minimal cross-resistance with cisplatin; Supplementary Figure S4. Inhibition of PP2A by LB100 sensitizes resistant ovarian cancer cells to cisplatin; Supplementary Figure S5. Western blots showing effect of LB100 on cell-cycle dependent kinases.
Supplementary Fig. S1 Legend from Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression
Authors: Nie Feng-qi , Sun Ming , Yang Jin-song , Xie Min , Xu Tong-peng , Xia Rui , Liu Yan-wen , Liu Xiang-hua , Zhang Er-bao , Lu Kai-hua , Shu Yong-qian
Published: April 2023

Supplementary Fig. S1 Legend
Supplementary Figure Legends from Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes
Authors: Fink Lauren S. , Beatty Alexander , Devarajan Karthik , Peri Suraj , Peterson Jeffrey R.
Published: April 2023

Supplementary Figure Legends
Data Supplement from Calpain-Mediated Integrin Deregulation as a Novel Mode of Action for the Anticancer Gallium Compound KP46
Authors: Jungwirth Ute , Gojo Johannes , Tuder Theresa , Walko Gernot , Holcmann Martin , Schöfl Thomas , Nowikovsky Karin , Wilfinger Nastasia , Schoonhoven Sushilla , Kowol Christian R. , Lemmens-Gruber Rosa , Heffeter Petra , Keppler Bernhard K. , Berger Walter
Published: April 2023

Legends to all supplementary figures and the video
Supplemental Figure 1 from Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells
Authors: Tsai Yu-Chieh , Ho Pei-Yin , Tzen Kai-Yuan , Tuan Tsung-Fan , Liu Wei-Lin , Cheng Ann-Lii , Pu Yeong-Shiau , Cheng Jason Chia-Hsien
Published: April 2023

The representative pictures of annexin V-stained T24 and NTUB1 cells under fluorescence microscopy
Supplemental Figure Legends from An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma
Authors: Lamhamedi-Cherradi Salah-Eddine , Menegaz Brian A. , Ramamoorthy Vandhana , Aiyer Ramani A. , Maywald Rebecca L. , Buford Adrianna S. , Doolittle Dannette K. , Culotta Kirk S. , O'Dorisio James E. , Ludwig Joseph A.
Published: April 2023

Supplemental Figure Legends. Legends for all the four supplemental figures
Supplemental Figure 4 from An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma
Authors: Lamhamedi-Cherradi Salah-Eddine , Menegaz Brian A. , Ramamoorthy Vandhana , Aiyer Ramani A. , Maywald Rebecca L. , Buford Adrianna S. , Doolittle Dannette K. , Culotta Kirk S. , O'Dorisio James E. , Ludwig Joseph A.
Published: April 2023

Supplemental Figure 4. Proteomic analysis of sensitive and resistant ES cell lines to YK-4-279
Supplementary Table 3 from Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D
Authors: He Ningning , Kim Nayoung , Song Mee , Park Choa , Kim Somin , Park Eun Young , Yim Hwa Young , Kim Kyunga , Park Jong Hoon , Kim Keun Il , Zhang Fan , Mills Gordon B. , Yoon Sukjoon
Published: April 2023

Supplementary Table 3: List of STK11-associated markers in lung cancer cell lines
Supplementary Figure 1 from Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D
Authors: He Ningning , Kim Nayoung , Song Mee , Park Choa , Kim Somin , Park Eun Young , Yim Hwa Young , Kim Kyunga , Park Jong Hoon , Kim Keun Il , Zhang Fan , Mills Gordon B. , Yoon Sukjoon
Published: April 2023

Supplementary Figure 1: Transfection efficacy of siRNA treatment
Supplemental Figure 1 from Changes in BAI1 and Nestin Expression Are Prognostic Indicators for Survival and Metastases in Breast Cancer and Provide Opportunities for Dual Targeted Therapies
Authors: Meisen Walter Hans , Dubin Samuel , Sizemore Steven T. , Mathsyaraja Haritha , Thies Katie , Lehman Norman L. , Boyer Peter , Jaime-Ramirez Alena Cristina , Elder J. Bradley , Powell Kimerly , Chakravarti Arnab , Ostrowski Michael C. , Kaur Balveen
Published: April 2023

Supplemental Figure 1: The ability of 34.5ENVE to infect and replicate in DB-7 and Met-1 BC cells
Supplemental table 2 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
Authors: Yarar Defne , Lahdenranta Johanna , Kubasek William , Nielsen Ulrik B. , MacBeath Gavin
Published: April 2023

Table showing raw values of tumor sizes of OVCAR8 EV-neg, H1047R-neg, and H1047R-ErbB3 expressing xenografts.
Supplementary Fig. 3 from Small Molecule Inhibition of MDM2–p53 Interaction Augments Radiation Response in Human Tumors
Authors: Werner Lauryn R. , Huang Shyhmin , Francis David M. , Armstrong Eric A. , Ma Fang , Li Chunrong , Iyer Gopal , Canon Jude , Harari Paul M.
Published: April 2023

Supplementary Fig. 3. Induction of cellular senescence by AMG 232 and radiation.
Supplemental Figure 4 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
Authors: Yarar Defne , Lahdenranta Johanna , Kubasek William , Nielsen Ulrik B. , MacBeath Gavin
Published: April 2023

Growth rates of engineered OVCAR8 cells grown as spheroids.
Supplemental Figure 9 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
Authors: Theodosakis Nicholas , Held Matthew A. , Marzuka-Alcala Alexander , Meeth Katrina M. , Micevic Goran , Long Georgina V. , Scolyer Richard A. , Stern David F. , Bosenberg Marcus W.
Published: April 2023

Supplemental Figure 9. Inhibition of proteosomal degradation is insufficient to prevent loss of hexokinase II
Supplementary Figure 5 from A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation
Authors: Ott Heidi M. , Graves Alan P. , Pappalardi Melissa B. , Huddleston Michael , Halsey Wendy S. , Hughes Ashley M. , Groy Arthur , Dul Edward , Jiang Yong , Bai Yuchen , Annan Roland , Verma Sharad K. , Knight Steven D. , Kruger Ryan G. , Dhanak Dashyant , Schwartz Benjamin , Tummino Peter J. , Creasy Caretha L. , McCabe Michael T.
Published: April 2023

Supplementary Figure 5: H3K27me3 enrichment across genes modulated by EZH2 inhibition
Supplementary Data-Combination Response from An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
Authors: O'Neil Jennifer , Benita Yair , Feldman Igor , Chenard Melissa , Roberts Brian , Liu Yaping , Li Jing , Kral Astrid , Lejnine Serguei , Loboda Andrey , Arthur William , Cristescu Razvan , Haines Brian B. , Winter Christopher , Zhang Theresa , Bloecher Andrew , Shumway Stuart D.
Published: April 2023

raw combination response data; response is represented as fractional viability
Supplementary Fig. S1 from Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer
Authors: Chen Long , Li Jie , Farah Elia , Sarkar Sukumar , Ahmad Nihal , Gupta Sanjay , Larner James , Liu Xiaoqi
Published: April 2023

LNCaP cells were infected with lentivirus to overexpress Plk1, treated as indicated, tested for cell Viability.
Supplemental Table 1. Thirty-nine cell lines used in combination screen. from An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
Authors: O'Neil Jennifer , Benita Yair , Feldman Igor , Chenard Melissa , Roberts Brian , Liu Yaping , Li Jing , Kral Astrid , Lejnine Serguei , Loboda Andrey , Arthur William , Cristescu Razvan , Haines Brian B. , Winter Christopher , Zhang Theresa , Bloecher Andrew , Shumway Stuart D.
Published: April 2023

RAS mutation/signature does not predict response to mTOR/Wee1 combination.
Table S1 from HPMA–Copolymer Nanocarrier Targets Tumor-Associated Macrophages in Primary and Metastatic Breast Cancer
Authors: Zimel Melissa N. , Horowitz Chloe B. , Rajasekhar Vinagolu K. , Christ Alexander B. , Wei Xin , Wu Jianbo , Wojnarowicz Paulina M. , Wang Dong , Goldring Steven R. , Purdue P. Edward , Healey John H.
Published: April 2023

Copolymer composition
Supplementary Figure 1 from Near Infrared Photoimmunotherapy in a Transgenic Mouse Model of Spontaneous Epidermal Growth Factor Receptor (EGFR)-expressing Lung Cancer
Authors: Nakamura Yuko , Ohler Zoe Weaver , Householder Deborah , Nagaya Tadanobu , Sato Kazuhide , Okuyama Shuhei , Ogata Fusa , Daar Dagane , Hoa Tieu , Choyke Peter L. , Kobayashi Hisataka
Published: April 2023

Scheme of Ab-IR700 structure
Supplementary Figures 1 through 3 and Supplementary Table 1 from Phosphoproteomic Profiling Identifies Focal Adhesion Kinase as a Mediator of Docetaxel Resistance in Castrate-Resistant Prostate Cancer
Authors: Lee Brian Y. , Hochgräfe Falko , Lin Hui-Ming , Castillo Lesley , Wu Jianmin , Raftery Mark J. , Martin Shreeve S. , Horvath Lisa G. , Daly Roger J.
Published: April 2023

PDF - 260KB, Supplementary Figure 1. Validation of the Docetaxel-resistant prostate cancer cell line DU145-Rx. Supplementary Figure 1. Validation of the Docetaxel-resistant prostate cancer cell line DU145-Rx. Supplementary Figure 3. Co-treatment-induced cell death in Docetaxel-resistant DU145-Rx cells is associated with enhanced autophagy. Supplementary Table 1. SILAC ratios of up- or down-regulated tyrosine phosphorylation sites.
Supplementary Table S2 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Authors: Buatois Vanessa , Johnson Zoë , Salgado-Pires Susana , Papaioannou Anne , Hatterer Eric , Chauchet Xavier , Richard Françoise , Barba Leticia , Daubeuf Bruno , Cons Laura , Broyer Lucile , D'Asaro Matilde , Matthes Thomas , LeGallou Simon , Fest Thierry , Tarte Karin , Clarke Hinojosa Robert K. , Genescà Ferrer Eulàlia , Ribera José María , Dey Aditi , Bailey Katharine , Fielding Adele K. , Eissenberg Linda , Ritchey Julie , Rettig Michael , DiPersio John F. , Kosco-Vilbois Marie H. , Masternak Krzysztof , Fischer Nicolas , Shang Limin , Ferlin Walter G.
Published: April 2023

Supplementary Table S2 shows the cell surface density (expressed as number of receptors per cell) for CD19, CD47, CD20 on different human tumor cell lines.
Supplementary Table 1 from RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE
Authors: Suthe Sreedhar Reddy , Yao Hang-Ping , Weng Tian-Hao , Hu Chen-Yu , Feng Liang , Wu Zhi-Gang , Wang Ming-Hai
Published: April 2023

Table S1 is about the levels of RON expression in 168 primary TNBC samples analyzed by anti-RON mAb IHC staining
Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Authors: Oberst Michael D. , Augé Catherine , Morris Chad , Kentner Stacy , Mulgrew Kathy , McGlinchey Kelly , Hair James , Hanabuchi Shino , Du Qun , Damschroder Melissa , Feng Hui , Eck Steven , Buss Nicholas , de Haan Lolke , Pierce Andrew J. , Park Haesun , Sylwester Andrew , Axthelm Michael K. , Picker Louis , Morris Nicholas P. , Weinberg Andrew , Hammond Scott A.
Published: April 2023

Supplementary Methods
Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Authors: Oberst Michael D. , Augé Catherine , Morris Chad , Kentner Stacy , Mulgrew Kathy , McGlinchey Kelly , Hair James , Hanabuchi Shino , Du Qun , Damschroder Melissa , Feng Hui , Eck Steven , Buss Nicholas , de Haan Lolke , Pierce Andrew J. , Park Haesun , Sylwester Andrew , Axthelm Michael K. , Picker Louis , Morris Nicholas P. , Weinberg Andrew , Hammond Scott A.
Published: April 2023

Expression of cell surface Fc gamma receptors on human cells
Figure S3 from Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation
Authors: Singh Pankaj K. , Deorukhkar Amit A. , Venkatesulu Bhanu P. , Li Xiaolin , Tailor Ramesh , Bomalaski John S. , Krishnan Sunil
Published: April 2023

RPPA data
Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Authors: Hao Huai-Xiang , Wang Hongyun , Liu Chen , Kovats Steven , Velazquez Roberto , Lu Hengyu , Pant Bhavesh , Shirley Matthew , Meyer Matthew J. , Pu Minying , Lim Joanne , Fleming Michael , Alexander LeighAnn , Farsidjani Ali , LaMarche Matthew J. , Moody Susan , Silver Serena J. , Caponigro Giordano , Stuart Darrin D. , Abrams Tinya J. , Hammerman Peter S. , Williams Juliet , Engelman Jeffrey A. , Goldoni Silvia , Mohseni Morvarid
Published: April 2023

Supplementary Material and Methods. File contains the following: Transcriptome sequencing and analysis, Soft agar assay, 2D and 3D Cell proliferation screen and compound characterization information.
Supplementary Figure S7 from Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models
Authors: Moore Heather M. , Savage Heidi M. , O'Brien Carol , Zhou Wei , Sokol Ethan S. , Goldberg Michael E. , Metcalfe Ciara , Friedman Lori S. , Lackner Mark R. , Wilson Timothy R.
Published: April 2023

Supplementary Figure S7: MCF-7 DOX-inducible ER-alpha overexpressing cells without DOX induction respond similarly to taselisib and/or fulvestrant as MCF-7 parental cells.
Supplementary Figure S3 from Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models
Authors: Moore Heather M. , Savage Heidi M. , O'Brien Carol , Zhou Wei , Sokol Ethan S. , Goldberg Michael E. , Metcalfe Ciara , Friedman Lori S. , Lackner Mark R. , Wilson Timothy R.
Published: April 2023

Supplementary Figure S3: In vitro effects of PTEN loss on taselisib sensitivity in PIK3CA-mutant breast cancer cells.
Supplemental Fig. S2 from Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown
Authors: Hu Shanhu , Lu Yun , Orr Bernardo , Godek Kristina , Mustachio Lisa Maria , Kawakami Masanori , Sekula David , Compton Duane A. , Freemantle Sarah , Dmitrovsky Ethan
Published: April 2023

Effects of Ser 170 and Thr 194 CDK phosphorylation sites of CP110 on CDK2-inhibitior-mediated anaphase catastrophe in human lung cancer cells. (A) Hop62 cells were transfected with CP110-MUT with indicated phosphorylation sites returned to wild-type sequence. Twenty four hours after transfection, cells were treated with seliciclib (10 μM) for 24 hours and fixed and scored for multipolar anaphases. (B) Hop62 cells were transfected with a CP110-WT vector with indicated phosphorylation sites replaced with alanine residues. Twenty four hours after transfection, cells were treated with seliciclib (10 μM) for 24 hours and fixed and scored for multipolar anaphases. The symbols indicate * P < 0.05 and ** P < 0.01.
Figure S4 from Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1–Mediated Lung Cancer
Authors: Shin Dong Hoon , Jo Jeong Yeon , Han Ji-Youn
Published: April 2023

Levels of phosphorylated ERBB2, ERBB3, ERK, and AKT, and cleaved caspase 3 and the number of TUNEL-positive cells were assessed by immunohistochemistry in tumor tissues from mice treated as indicated in Fig 5 collected at the end of the experiment.
Supplementary Tables S1-S6 and Supplementary Figures S1-S2 from BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers
Authors: Tang Zhiyu , Yuan Xi , Du Rong , Cheung Shing-Hu , Zhang Guoliang , Wei Jing , Zhao Yuan , Feng Yingcai , Peng Hao , Zhang Yi , Du Yunguang , Hu Xiaoxia , Gong Wenfeng , Liu Yong , Gao Yajuan , Liu Ye , Hao Rui , Li Shengjian , Wang Shaohui , Ji Jiafu , Zhang Lianhai , Li Shuangxi , Sutton David , Wei Min , Zhou Changyou , Wang Lai , Luo Lusong
Published: April 2023

Supplementary Tables S1-S6 and Supplementary Figures S1-S2. Table S1: Data collection and refinement statistics, related to Figure 1B; Table S2: Summary of cell line related information; Table S3: BGB-283 is a reversible B-RAF inhibitor; Table S4. Kinase inhibition profile of BGB-283. BGB-283 selectively inhibited multiple kinases at concentration of 10 μM; Table S5: IC50 values of BGB-283 in inhibiting various kinases; Table S6. Anti-tumor efficacy of BGB-283 in CRC xenograft models; Figure S1: BGB-283 is a slow-off B-RAF inhibitor showing potent anti-EGFR activity in multiple cell lines; Figure S2. The effect of BGB-283 on body weight of nude mice subcutaneously implanted with human cancer xenografts.
Supplementary Figure 5 from Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Authors: Zoeller Jason J. , Vagodny Aleksandr , Taneja Krishan , Tan Benjamin Y. , O'Brien Neil , Slamon Dennis J. , Sampath Deepak , Leverson Joel D. , Bronson Roderick T. , Dillon Deborah A. , Brugge Joan S.
Published: April 2023

p63 MCL-1 HER3 post-treatment.
Supplementary Figure 5 - Activity of targeted (XE) and non-targeted (KSF) mTNF, hIL2 and mIFNa2 in BALB/c mice bearing CT26 tumors transfected with human CAIX. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
Authors: Ziffels Barbara , Stringhini Marco , Probst Philipp , Fugmann Tim , Sturm Theo , Neri Dario
Published: April 2023

a, b, c) Tumor bearing mice received three injections of either 2 Âµg XE-mTNF or 2 Âµg KSF-mTNF(a), 30 Âµg XE-hIL2 or 30 Âµg KSF-hIL2(b) or 80 Âµg XE-mIFNa2 or 80 Âµg KSF-mIFNa2(c)or saline (PBS) as control, starting when tumors reached a size of 90 mm3. Data are represented as mean (n=3) + SEM. Statistical significance is shown on day 15, n.s.=non-significant, *p<0.05, ***p<0.0005, ****p<0.0001. d, e, f) Body weight change during the treatment phase of the therapies depicted in a, b, c. g) Pictures of representative tumor growth taken before (day 7) and after treatment (day 12).
Supplemental Table 2 from Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention
Authors: Mallery Susan R. , Wang Daren , Santiago Brian , Pei Ping , Bissonnette Caroline , Jayawardena Jayanetti Asiri , Schwendeman Steven P. , Spinney Richard , Lang James
Published: April 2023

High levels of cell vitality were maintained during cell treatments
Supplementary Methods from R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis
Authors: Guo Yuna , Kenney S. Ray , Muller Carolyn Y. , Adams Sarah , Rutledge Teresa , Romero Elsa , Murray-Krezan Cristina , Prekeris Rytis , Sklar Larry A. , Hudson Laurie G. , Wandinger-Ness Angela
Published: April 2023

Method of immunofluorescence for the ovarian cancer cell identification
Supplementary Figure Legends from R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis
Authors: Guo Yuna , Kenney S. Ray , Muller Carolyn Y. , Adams Sarah , Rutledge Teresa , Romero Elsa , Murray-Krezan Cristina , Prekeris Rytis , Sklar Larry A. , Hudson Laurie G. , Wandinger-Ness Angela
Published: April 2023

Legends for the supplementary figures
Supplementary Figure S5 from A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition
Authors: Kim Eun Hye , Jang Hyejin , Roh Jong-Lyel
Published: April 2023

Supplementary Figure S5. DPP-23 prevents the loss of daily oral food intake and body weight by cisplatin. (A) Comparison of daily oral food intake among the different treatment groups. The oral food intake was measured daily after treatment initiation, and the intake of each group is shown as the fold change over that of the control group. The error bars represent the standard error; *P < 0.01. (B) Changes in body weight among mice receiving different treatments. The error bars represent the standard error; *P < 0.01.
Supplementary Figure legends S1-3 from Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63
Authors: de Goeij Bart E.C.G. , Vink Tom , ten Napel Hendrik , Breij Esther C.W. , Satijn David , Wubbolts Richard , Miao David , Parren Paul W.H.I.
Published: April 2023

Supplementary Figure legends for figures S1, S2 and S3
Supplementary Fig. S4 from Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design
Authors: Lee Nam-Kyung , Su Yang , Bidlingmaier Scott , Liu Bin
Published: April 2023

Bispecific ADC and site-specific drug conjugation.
Supplementary Figure S1 from Targeting Homologous Recombination by Pharmacological Inhibitors Enhances the Killing Response of Glioblastoma Cells Treated with Alkylating Drugs
Authors: Berte Nancy , Piée-Staffa Andrea , Piecha Nadine , Wang Mengwan , Borgmann Kerstin , Kaina Bernd , Nikolova Teodora
Published: April 2023

Structures of CCNU and HR inhibitors
Supplementary Table S3 from The Novel Small-Molecule SR18662 Efficiently Inhibits the Growth of Colorectal Cancer In Vitro and In Vivo
Authors: Kim Julie , Wang Chao , de Sabando Ainara Ruiz , Cole Hannah L. , Huang Timothy J. , Yang Jie , Bannister Thomas D. , Yang Vincent W. , Bialkowska Agnieszka B.
Published: April 2023

Statistical analysis of apoptosis assay.
Supplementary Figure S2 from Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
Authors: Elbanna May , Orillion Ashley R. , Damayanti Nur P. , Adelaiye-Ogala Remi , Shen Li , Miles Kiersten Marie , Chintala Sreenivasulu , Ciamporcero Eric , Ramakrishnan Swathi , Ku Sheng-yu , Rex Karen , Caenepeel Sean , Coxon Angela , Pili Roberto
Published: April 2023

Supplementary Figure S2 shows additional tumor growth data
Supplementary Data from Microvesicle-Mediated Delivery of Minicircle DNA Results in Effective Gene-Directed Enzyme Prodrug Cancer Therapy
Authors: Kanada Masamitsu , Kim Bryan D. , Hardy Jonathan W. , Ronald John A. , Bachmann Michael H. , Bernard Matthew P. , Perez Gloria I. , Zarea Ahmed A. , Ge T. Jessie , Withrow Alicia , Ibrahim Sherif A. , Toomajian Victoria , Gambhir Sanjiv S. , Paulmurugan Ramasamy , Contag Christopher H.
Published: April 2023

Supplementary figures
Supplementary Materials and Methods from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
Authors: Geretti Elena , Leonard Shannon Curtis , Dumont Nancy , Lee Helen , Zheng Jinzi , De Souza Raquel , Gaddy Daniel F. , Espelin Christopher W. , Jaffray David A. , Moyo Victor , Nielsen Ulrik B. , Wickham Thomas J. , Hendriks Bart S.
Published: April 2023

Supplementary Materials and Methods. This file contains information on the reagents, methods for the evaluation of cell viability, preparation of liposomes and details on the image analysis.
Supplemental Figure 1 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Authors: Flynn Michael J. , Zammarchi Francesca , Tyrer Peter C. , Akarca Ayse U. , Janghra Narinder , Britten Charles E. , Havenith Carin E.G. , Levy Jean-Noel , Tiberghien Arnaud , Masterson Luke A. , Barry Conor , D'Hooge Francois , Marafioti Teresa , Parren Paul W.H.I. , Williams David G. , Howard Philip W. , van Berkel Patrick H. , Hartley John A.
Published: April 2023

DAR determination by SEC, RPLC and HIC
Supplementary Figure S3 from Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer
Authors: Ide Hiroki , Inoue Satoshi , Mizushima Taichi , Jiang Guiyang , Chuang Kuang-Hsiang , Oya Mototsugu , Miyamoto Hiroshi
Published: April 2023

Effects of inhibitors of DNA repair on the cytotoxicity of irradiation in bladder cancer cells.